Evaluation of a Simplified Protocol for Regional Citrate Anticoagulation in Continuous Venovenous Hemodiafiltration
Status:
Completed
Trial end date:
2008-03-01
Target enrollment:
Participant gender:
Summary
Dialysis requires thinning of the blood to prevent clotting in the dialysis machine. Thinning
of the blood is necessary but some forms of blood thinners may cause bleeding. Therefore,
researchers are seeking ways to minimize bleeding risks and ensure effective dialysis.
One medication used to thin the blood in the dialysis machine is citrate. Citrate has the
advantage of having its blood-thinning properties quickly reversed by calcium in the
patient's blood. As a consequence, only the blood in the machine is thinned, greatly reducing
the risk of bleeding when dialysis is carried out using other blood thinners. Until now, most
patients who received citrate for dialysis were administered the citrate in a separate
infusion through an IV pump into the dialysis machine. This method requires complex
monitoring and calculations. This study is about Prismocitrate which is a dialysis fluid very
similar to the regular dialysis fluid that is used in this intensive care unit, except that
this fluid already contains exactly the correct amount of citrate. Thus, this method does not
require a separate pump for citrate and calculations to pump the citrate into the blood as it
goes through the kidney machine. Having the citrate already contained in the dialysis fluid
simplifies the procedure and reduces the possibility of calculation errors.
This study seeks to determine if this simplified means of providing blood thinning in the
kidney machine also results in the correct balance of blood salts.